Method of treating dyslipidemic disorders

a dyslipidemic disorder and treatment method technology, applied in the field of dyslipidemic disorders, can solve the problems of reducing serum cholesterol levels by about 20%, side effects and qualifying patient population, and hdls serum levels are regarded as negative risk factors, so as to improve patient comfort, improve the stability of apoa-i complexes, and facilitate administration.
US20040067873A1Inactive Publication Date: 2004-04-08PFIZER INC
7 Cites 50 Cited by

Patent Information

Authority / Receiving Office
US · United States
Current Assignee / Owner
PFIZER INC
Publication Date
2004-04-08
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
Patent Text Reader

Abstract

The invention provides methods of treating or preventing a condition or disorder associated with dyslipidemia with compositions comprising apolipoprotein-sphingomyelin complexes. The methods of the invention permit reduction, by 4- to 20-fold, of the amount of apolipoprotein required for therapeutic administration to bring about an ameliorative effect.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims priority to U.S. Provisional Application Serial Number 60 / 381,512, filed May 17, 2002, incorporated herein by reference in its entirety.1. TECHNICAL FIELD

[0002] The invention provides methods of treating or preventing a disease, condition or disorder associated with dyslipidemia with apolipoprotein-sphingomyelin complexes or pharmaceutical compositions thereof. The invention further provides compositions for treating or preventing a disease, condition or disorder associated with dyslipidemia and methods for the production of the compositions.2. BACKGROUND OF THE INVENTION

[0003] Circulating cholesterol is carried by plasma lipoproteins--complex particles of lipid and protein composition that transport lipids in the blood. Four major classes of lipoprotein particles circulate in plasma and are involved in the fat-transport system: chylomicrons, very low density lipoprotein (VLDL), low density lipoprotein (LDL) and high density lipoprotein (HDL). Chylomic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More